Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

154.00 +2.13 (+1.40%)
Official Closing Price Updated: 7:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Forever Favorites: 7 Dividend Stocks to Buy and Never Sell
There's no better investment strategy than choosing dividend stocks to buy and hold as the provide income and capital appreciation 
Via InvestorPlace
7 New Year’s Stocks to Buy to Get 2024 Off to a Bright Start
With one year down and another soon coming up, investors should take the time to consider these stocks to buy for 2024. 
Via InvestorPlace
Why NYSE:JNJ qualifies as a good dividend investing stock.
Uncovering Dividend Opportunities with JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
3 Healthcare Stocks That Could Help Make You a Millionaire
These stocks each have reached an important turning point that could signal growth ahead. 
Via The Motley Fool
3 of the Most Attractive Dividend Stocks in the Pharma Space
Discover the resilience and growth potential of pharma dividend stocks, offering stability and consistency in the healthcare sphere. 
Via InvestorPlace
Johnson & Johnson Unusual Options Activity
Via Benzinga
2 Top Dividend Stocks to Buy Now
You can snap up these particular dividend stocks for a bargain today. 
Via The Motley Fool
(JNJ) - Analyzing Johnson & Johnson's Short Interest
Via Benzinga
The Dogs of the Dow May Pay Big Dividends in 2024
The dogs of the Dow could be great buys in 2024 for investors looking to take a chance on some underdogs that pay dividends too. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
The 7 Most Undervalued Dividend Stocks to Buy in December
Enjoy passive income throughout 2024 and watch your investment grow with these dividend stocks to buy this month. 
Via InvestorPlace
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with... 
Via Benzinga
3 Dow Stocks I Wouldn’t Touch With a 10-Foot Pole
Just because the Dow 30 is supposed to serve as a bellwether for the American economy doesn't mean there aren't some Dow stocks to avoid. 
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
Ryan Cohen Plans to Save GameStop By Becoming Warren Buffett
Ryan Cohen's latest plan to save GME stock is transforming GameStop into Berkshire Hathaway. Will it work? 
Via InvestorPlace
Rain Oncology Goes Private Just Two Years After $120M NASDAQ Debut
Rain Oncology Inc (NASDAQ: RAIN) has agreed to be acquired by Pathos AI Inc. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Neurosurgery Focused Integra LifeSciences Bolsters Its ENT Portfolio With $275M Acquisition Deal
Integra LifeSciences Holdings Corporation (NASDAQ: IART) agreed to acquire Acclarent Inc. 
Via Benzinga
Economic Safety Nets: 7 Defensive Stocks Providing Portfolio Stability
Although some signs of economic progress is seen, other signs suggest that investors should consider defensive stock picks. 
Via InvestorPlace
D.R. Horton To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Seeking Passive Income? 7 Dividend Stocks You Don’t Want to Miss.
Are you looking for passive income through dividend stocks? Here are seven dividend stocks you don't want to miss. 
Via InvestorPlace
Asana sold the rip. Is it time to buy the dip?
Asana stock plunged as investors sold the news on its bullish earnings report, but with the company raising guidance, it may be time for investors buy the dip - 
Via MarketBeat
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
Life-Changing Investments: 3 Stocks That Will Set You Up for the Long Haul
Buying stocks with long-term growth potential regardless of the market ensures you will own future-proof investments to create wealth. 
Via InvestorPlace
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or  
Via Benzinga
Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion... 
Via Benzinga
5 Phenomenal Stocks in Warren Buffett's "Secret" Portfolio That Are Screaming Buys in 2024
The Oracle of Omaha's $610 million hidden portfolio has five amazing bargains hiding in plain sight. 
Via The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
A weekly look at top trending tickers seeing increased attention from Benzinga users. 
Via Benzinga
7 Tech Stocks to Light Up Your Portfolio This Holiday Season
Are you looking for the best tech stocks this holiday season? Here are seven stocks to light up your portfolio this holiday season. 
Via InvestorPlace
Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
Investing in the Aging Population: 3 Healthcare Stocks to Watch
America is becoming a much older country on average. These three healthcare stocks are ideally positioned for this demographic shift. 
Via InvestorPlace
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. 
Via Benzinga
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS